Goldman's Terence Flynn says a study published in a medical journal suggests branded VEGF drugs such as Regeneron's (REGN +2.7%) Eylea "are superior to off-label Avastin." In the cited study, patients on Lucentis realized a 13 letter improvement in vision versus an 11 letter improvement for those on Avastin.
Goldman's Terence Flynn says a study published in a medical journal suggests branded VEGF drugs...
Recommended For You
About REGN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
REGN | - | - |
Regeneron Pharmaceuticals, Inc. |